Skip to content

Author

Ajay Sheshadri

We have 3 of 25 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Incidence and risk factors for pneumonitis in urothelial carcinoma treated with enfortumab vedotin plus pembrolizumab: retrospective study

Abstract Background Enfortumab vedotin plus pembrolizumab (EVP) is first-line standard therapy for locally advanced or metastatic urothelial carcinoma (LA/mUC), but real-world pneumonitis incidence and predictors remain poorly characterized. Material and methods We conducted a retrospective cohort study of patients wit...

Luis Angel Diaz Tejada, Fabiana Alexandra Príncipe Osorio, A. Attia et al. · 0 citations
Open access Sep 2026

Trastuzumab Deruxtecan-Associated Pneumonitis in Non-Breast Solid Tumors: A Retrospective Cohort Study

Introduction Trastuzumab deruxtecan (T-DXd) has transformed treatment for HER2-expressing malignancies, yet pneumonitis remains a potentially fatal toxicity. Most pneumonitis data derive from breast cancer cohorts, but risk factors and outcomes in non-breast solid organ tumors are poorly characterized. Materials and Me...

A. Attia, Jose Carlos Tuesta Delgado, Alexia Dayan Lecaros Zavalla et al. · 0 citations
Review Open access Sep 2026

The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact

This position article synthesizes key barriers in ICI therapy while highlighting emerging opportunities to refine patient selection, improve safety, and enhance therapeutic durability, position the field to move beyond the current plateau toward a more precise, effective, and patient-centered era of immuno-oncology.

Joud Hajjar, B. Stephen, A. Aaroe et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.